NCT04949503 - A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN | Biotech Hunter

Enrollment

1,931

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

March 15, 2023

Study Completion Date

April 30, 2023

Conditions

Locally Advanced Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

nimotuzumab

Patients in the study group were received nimotuzumab on the basis of chemoradiotherapy (control group).

Trial Locations (5)

Beijing Cancer Hospital, Beijing

The General Hospital of the People's Liberation Army, Beijing

Tianjin Cancer Hospital, Tianjin

Sun Yat-sen University Cancer Centre, Guangzhou

First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an